[1]
Bujor IE, Lozneanu L, Ursache A, Cristofor A, Scurtu AM, Plamadeala P, Gireada R, Mandici CE, Găină MA, Matasariu DR. Primary Clear Cell Adenocarcinoma of the Uterine Cervix in a 14-Year-Old Virgin Girl: Case Report. International journal of environmental research and public health. 2022 Dec 11:19(24):. doi: 10.3390/ijerph192416652. Epub 2022 Dec 11
[PubMed PMID: 36554533]
Level 3 (low-level) evidence
[2]
Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. The New England journal of medicine. 1971 Apr 22:284(15):878-81
[PubMed PMID: 5549830]
[3]
Teixeira JC, Santos DZ, Campos CS, Vale DB, Bragança JF, Zeferino LC. Cervical cancer in women under 25 years of age and outside the screening age: Diagnosis profile and long-term outcomes. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2021 Jul:154(1):150-156. doi: 10.1002/ijgo.13553. Epub 2021 Jan 27
[PubMed PMID: 33341962]
[4]
Liu Y, Shi X, Yang J, Zhou H, Peng P, Cao D. Clinical Features and Prognostic Factors of Cervical Clear Cell Adenocarcinoma: A Retrospective Analysis of 74 Cases from a Tertiary Hospital. Technology in cancer research & treatment. 2023 Jan-Dec:22():15330338221149297. doi: 10.1177/15330338221149297. Epub
[PubMed PMID: 36718531]
Level 2 (mid-level) evidence
[5]
Secosan C, Balint O, Ilian A, Balan L, Balulescu L, Motoc A, Zahoi D, Grigoras D, Pirtea L. New Insights in the Diagnosis of Rare Adenocarcinoma Variants of the Cervix-Case Report and Review of Literature. Healthcare (Basel, Switzerland). 2022 Jul 28:10(8):. doi: 10.3390/healthcare10081410. Epub 2022 Jul 28
[PubMed PMID: 36011067]
Level 3 (low-level) evidence
[6]
Huo D, Anderson D, Palmer JR, Herbst AL. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynecologic oncology. 2017 Sep:146(3):566-571. doi: 10.1016/j.ygyno.2017.06.028. Epub 2017 Jul 6
[PubMed PMID: 28689666]
[7]
Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer causes & control : CCC. 2010 Jul:21(7):999-1007. doi: 10.1007/s10552-010-9526-5. Epub 2010 Mar 4
[PubMed PMID: 20204493]
[8]
Sato T, Fukazawa Y, Ohta Y, Iguchi T. Involvement of growth factors in induction of persistent proliferation of vaginal epithelium of mice exposed neonatally to diethylstilbestrol. Reproductive toxicology (Elmsford, N.Y.). 2004 Nov:19(1):43-51
[PubMed PMID: 15336711]
[9]
Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology. 2006 Jun:147(6 Suppl):S11-7
[PubMed PMID: 16690809]
[10]
Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Archiv : an international journal of pathology. 2019 Nov:475(5):537-549. doi: 10.1007/s00428-019-02601-0. Epub 2019 Jun 17
[PubMed PMID: 31209635]
Level 3 (low-level) evidence
[11]
McMullan JC, Graham MJ, Craig EF, McCluggage WG, Hunter DH, Feeney L. The malignant transformation of endometriosis: Is there a left lateral predisposition of ovarian clear cell and endometrioid carcinomas? European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2024 Mar 6:50(6):108247. doi: 10.1016/j.ejso.2024.108247. Epub 2024 Mar 6
[PubMed PMID: 38522332]
[13]
Younis JS, Izhaki I. At what age endometriosis-associated ovarian cancer is diagnosed? The implications for women in the reproductive age. Frontiers in oncology. 2023:13():1193123. doi: 10.3389/fonc.2023.1193123. Epub 2023 May 23
[PubMed PMID: 37287920]
[14]
Stolnicu S, Karpathiou G, Guerra E, Mateoiu C, Reques A, Garcia A, Bart J, Felix A, Fanni D, Gama J, Hardisson D, Bennett JA, Parra-Herran C, Oliva E, Abu-Rustum N, Soslow RA, Park KJ. Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome: A Comprehensive Analysis of 58 Cases. The American journal of surgical pathology. 2022 Jun 1:46(6):765-773. doi: 10.1097/PAS.0000000000001863. Epub 2022 Jan 5
[PubMed PMID: 34985047]
Level 3 (low-level) evidence
[15]
Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. The American journal of surgical pathology. 2018 Feb:42(2):214-226. doi: 10.1097/PAS.0000000000000986. Epub
[PubMed PMID: 29135516]
[16]
Herbst AL. Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES). Gynecologic oncology. 2000 Feb:76(2):147-56
[PubMed PMID: 10637063]
[17]
Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, Liu FS, Fujino T, Barrett JC, McLachlan JA. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 1996 Feb 1:77(3):507-13
[PubMed PMID: 8630958]
[18]
Bocaneti F, Altamura G, Corteggio A, Velescu E, Borzacchiello G. Expression of bcl-2 and p53 in bovine cutaneous fibropapillomas. Infectious agents and cancer. 2015:10(1):2. doi: 10.1186/1750-9378-10-2. Epub 2015 Jan 12
[PubMed PMID: 25601891]
[19]
Nakamura K, Nakayama K, Minamoto T, Ishibashi T, Ohnishi K, Yamashita H, Ono R, Sasamori H, Razia S, Hossain MM, Kamrunnahar S, Ishikawa M, Ishikawa N, Kyo S. Lynch Syndrome-Related Clear Cell Carcinoma of the Cervix: A Case Report. International journal of molecular sciences. 2018 Mar 25:19(4):. doi: 10.3390/ijms19040979. Epub 2018 Mar 25
[PubMed PMID: 29587389]
Level 3 (low-level) evidence
[20]
Jiang X, Jin Y, Li Y, Huang HF, Wu M, Shen K, Pan LY. Clear cell carcinoma of the uterine cervix: clinical characteristics and feasibility of fertility-preserving treatment. OncoTargets and therapy. 2014:7():111-6. doi: 10.2147/OTT.S53204. Epub 2014 Jan 9
[PubMed PMID: 24470762]
Level 2 (mid-level) evidence
[21]
Yang L, Zheng A, Zhang X, Fang X, Sun W, Chen Y. Clear Cell Carcinoma of the Uterine Cervix: A Clinical and Pathological Analysis of 47 Patients Without Intrauterine Diethylstilbestrol Exposure. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2017 Jun:27(5):1009-1014. doi: 10.1097/IGC.0000000000000992. Epub
[PubMed PMID: 28498261]
Level 2 (mid-level) evidence
[22]
Huo D, Anderson D, Herbst AL. Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. The New England journal of medicine. 2018 May 3:378(18):1746-1748. doi: 10.1056/NEJMc1800097. Epub
[PubMed PMID: 29719188]
[23]
Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, Juretzka MM, Pirog EC. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. The American journal of surgical pathology. 2011 May:35(5):633-46. doi: 10.1097/PAS.0b013e31821534b9. Epub
[PubMed PMID: 21490443]
[24]
Mathew Thomas V, Alexander SA, Hadfield MJ, Vredenburgh J. A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure. Cureus. 2020 Apr 23:12(4):e7796. doi: 10.7759/cureus.7796. Epub 2020 Apr 23
[PubMed PMID: 32461864]
Level 3 (low-level) evidence
[25]
Ju B, Wang J, Yang B, Sun L, Guo Y, Hao Q, Wu J. Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2018 Jul:37(4):388-396. doi: 10.1097/PGP.0000000000000430. Epub
[PubMed PMID: 28796747]
Level 2 (mid-level) evidence
[26]
Merz J, Bossart M, Bamberg F, Eisenblaetter M. Revised FIGO Staging for Cervical Cancer - A New Role for MRI. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2020 Oct:192(10):937-944. doi: 10.1055/a-1198-5729. Epub 2020 Jul 30
[PubMed PMID: 32731266]
[27]
Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. International journal of radiation oncology, biology, physics. 2006 May 1:65(1):177-81
[PubMed PMID: 16545921]
[28]
Tantitamit T, Hamontri S, Rangsiratanakul L. Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. Gynecologic oncology reports. 2017 May:20():34-36. doi: 10.1016/j.gore.2017.02.008. Epub 2017 Feb 22
[PubMed PMID: 28275694]
Level 3 (low-level) evidence
[29]
Choi KH, Lee HC, Kim YS, Park W, Kim YB, Jung W, Kim KS, Eom KY, Kim JH, Lee JH. Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study. Gynecologic oncology. 2024 Mar:182():45-50. doi: 10.1016/j.ygyno.2024.01.019. Epub 2024 Jan 20
[PubMed PMID: 38246046]
Level 2 (mid-level) evidence
[30]
Wang D, Zhao C, Fu L, Liu Y, Zhang W, Xu T. Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol. Obstetrics and gynecology international. 2019:2019():9465375. doi: 10.1155/2019/9465375. Epub 2019 Mar 26
[PubMed PMID: 31049066]
Level 3 (low-level) evidence
[31]
Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R. Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol. Gynecologic oncology. 2000 Mar:76(3):331-5
[PubMed PMID: 10684706]
[32]
Diaz JP, Sonoda Y, Leitao MM, Zivanovic O, Brown CL, Chi DS, Barakat RR, Abu-Rustum NR. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecologic oncology. 2008 Nov:111(2):255-60. doi: 10.1016/j.ygyno.2008.07.014. Epub 2008 Aug 27
[PubMed PMID: 18755500]
[33]
Machida H, Iwata T, Okugawa K, Matsuo K, Saito T, Tanaka K, Morishige K, Kobayashi H, Yoshino K, Tokunaga H, Ikeda T, Shozu M, Yaegashi N, Enomoto T, Mikami M. Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate. Gynecologic oncology. 2020 Feb:156(2):341-348. doi: 10.1016/j.ygyno.2019.11.021. Epub 2019 Nov 23
[PubMed PMID: 31767188]
[34]
Lee YY, Park W, Huh SJ, Yoon A, Park JY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis. Anticancer research. 2013 Oct:33(10):4675-81
[PubMed PMID: 24123048]
[35]
Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecologic oncology. 2014 Jul:134(1):166-71. doi: 10.1016/j.ygyno.2014.04.049. Epub 2014 May 2
[PubMed PMID: 24793000]
Level 1 (high-level) evidence
[36]
Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. International journal of radiation oncology, biology, physics. 2012 Oct 1:84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24
[PubMed PMID: 22365621]
[37]
Liu Z, Li J, Gu H, Tu H, Liu G, Liu J. Clear Cell Adenocarcinoma of Uterine Cervix: A Single Institution Retrospective Experience. Frontiers in oncology. 2020:10():532748. doi: 10.3389/fonc.2020.532748. Epub 2020 Nov 13
[PubMed PMID: 33282724]
Level 2 (mid-level) evidence
[38]
Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecologic oncology. 2008 Jun:109(3):335-9. doi: 10.1016/j.ygyno.2008.02.007. Epub 2008 Apr 3
[PubMed PMID: 18394687]
[39]
Pors J, Segura S, Chiu DS, Almadani N, Ren H, Fix DJ, Howitt BE, Kolin D, McCluggage WG, Mirkovic J, Gilks B, Park KJ, Hoang L. Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study. The American journal of surgical pathology. 2021 Apr 1:45(4):498-506. doi: 10.1097/PAS.0000000000001612. Epub
[PubMed PMID: 33165093]
[40]
Jones WB, Koulos JP, Saigo PE, Lewis JL Jr. Clear-cell adenocarcinoma of the lower genital tract: Memorial Hospital 1974-1984. Obstetrics and gynecology. 1987 Oct:70(4):573-7
[PubMed PMID: 3627626]
[41]
Verheijen RH, Verloop J, Helmerhorst TJ. [DES Daughter--expertise remains necessary]. Nederlands tijdschrift voor geneeskunde. 2013:157(52):A6809
[PubMed PMID: 24382040]
[42]
Camp EA, Prehn AW, Shen J, Herbst AL, Strohsnitter WC, Hobday CD, Robboy SJ, Adam E. Factors associated with a lack of pap smear utilization in women exposed in utero to diethylstilbestrol. Journal of women's health (2002). 2015 Apr:24(4):308-15. doi: 10.1089/jwh.2014.4930. Epub 2015 Mar 13
[PubMed PMID: 25768943]
[43]
Hammes B, Laitman CJ. Diethylstilbestrol (DES) update: recommendations for the identification and management of DES-exposed individuals. Journal of midwifery & women's health. 2003 Jan-Feb:48(1):19-29
[PubMed PMID: 12589302]
[44]
Herbst AL, Robboy SJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. American journal of obstetrics and gynecology. 1974 Jul 1:119(5):713-24
[PubMed PMID: 4857957]
Level 3 (low-level) evidence
[45]
Zong L, Wang W, He Y, Cheng N, Xiang Y. Carcinoma of the lower female genital tract in patients with genitourinary malformations: a clinicopathologic analysis of 36 cases. Journal of Cancer. 2019:10(13):3054-3061. doi: 10.7150/jca.30486. Epub 2019 Jun 2
[PubMed PMID: 31281483]
Level 3 (low-level) evidence
[46]
Spörri S, Altermatt HJ, Dreher E, Hänggi W. Clear cell adenocarcinoma of the cervix associated with a rare genitourinary malformation. Obstetrics and gynecology. 2000 Nov:96(5 Pt 2):834-6
[PubMed PMID: 11094228]